“showed a trend”

Lower household income showed a trend toward association with higher FCR ( P =.05).

Nuclear NANOG expression showed a trend to associate with a higher grade of dysplasia (Fisher’s exact test p = 0.05) ( Table 1 ). 3.3.

2B ) showed a trend for shorter BCR with a median of 91 months (95% CI not computed) compared to 125 (111.5–158.5 months) in patients with low SOAT2 staining ( n = 247, Log rank p = 0.05).

However, AF1_FFF mutations had no significant effect on the expression of Pgr or Esr1 although Pgr expression on GD7.5 showed a trend of upregulation (p > 0.05).

Group A compared with Group B + C showed a trend (p = 0.05) toward more patients with > 70% of blood glucose levels in the target range (70–180 mg/dL) in the first focus week.

With the prolongation of storage time, the solubility of preserved egg white gel at 3 storage temperatures showed a trend of first decreasing and then increasing in S1 ( P < 0.05), the solubility in S4 increased first and then decreased ( P < 0.05), and there was no obvious change trend in S2 and S3 parts.

An integrated analysis of approved benralizumab and mepolizumab doses showed a trend of 9% reduction in moderate-to-severe exacerbations (RR = 0.91, 95% CI [0.83, 1.00], p = 0.05, level of evidence C) ( Figure 2 A).

Notably, the thermal hypersensitivity showed a trend to recover over weeks 2 to 4 (slope: 0.21 ± 0.02, t-value: 7.94, p < 0.05); see also the changes expressed as the MPE ( Figure S4A in Supplementary Materials ).

However, mitral valve repair showed a trend toward higher 10-year survival compared to valve replacement in both groups (87.5% vs. 76.8%; p = 0.05 and 65.9% vs. 37.5%; p = 0.01) ( Fig. 8 ).

Patients in each group showed a trend of gradual improvement after surgery ( P < 0.05).

The OS showed a trend that the higher the expression of SLCO1B3, the better the OS ( P < 0.05) (Fig. 1 D1,D2).

The amount of bleeding showed a trend towards major complications ( P = 0.05).

Notably, putrescine levels were significantly higher in the probiotic group at both weeks 4 and 8 ( P < 0.05), whereas glycine levels showed a trend toward increase at week 12 ( P = 0.050), following the probiotic-only phase.

While PPRH2 showed a trend toward greater single-agent activity, these differences were statistically significant only when comparing DOTAP to PPRH2 ( p < 0.05) and Sc9 to PPRH2 ( p < 0.01) ( Figure 3 A), indicating that this concentration was appropriately sub-cytotoxic for combination studies.

In subgroup analysis, hypertensive patients with high MDA were significantly older ( p = 0.03) and showed a trend towards higher systolic BP ( p = 0.05) compared to those with low MDA.

With the progression of treatment time, all 3 indices showed a trend of significant decrease ( P < 0.05).

Although sham‐operated mice showed a trend ( P =0.05) toward sensorimotor functions recovery between day 16 (score: 19/38) and day 21 (score: 25/38), LIP‐Pg mice maintained significantly lower and stable neurological scores (day 16 score: 12/38; day 21 score: 14/38) during the 7 days following stroke induction.

The pooled analysis using a random-effects model showed a trend toward improvement with BFR but failed to reach statistical significance (SMD = 0.97; 95% CI [− 0.00, 1.95]; P = 0.05) (Fig. 7 ).

In the range of a liquid–solid ratio of 20~60 mL/g, with the increase in the liquid–solid ratio, the scavenging activity AVE to oxidizing free radicals showed a trend of first increasing and then gradually decreasing ( p < 0.05).

Notably, immediate post-procedural angiography showed a trend toward superior results in the drug coated balloon group in terms of MLD, DS%, and acute lumen gain ( p < 0.05) (Table S3 and Table 4 ).

Semiquantitative WB analysis showed a trend to increase in TOM20/actin ratio ( P = 0.05), which suggests an increase in mitochondrial number or mitochondrial dimensions in YS compared to WT fibers of FDB muscles ( Figure 4A ).

GLS showed a trend toward correlation with galectin-3 (Spearman’s R = 0.344, P = 0.05).

Human subjects showed a trend of diminishing reaction times as a function of Go-time (linear regression, slope = −20 ms/s, p < 0.05), which could reflect the anticipation of trial termination (increasing hazard rate).

It is noteworthy that abemaciclib (50 mg/kg) showed a trend of weight loss in the last few days of the experiment ( Figure 7C ) ( p < 0.05), which was not observed in the LPM3770277 treatment group ( Figure 7F ).

Thrombomodulin levels showed a trend toward positive correlation with syndecan-1 ( Figure 3 f, r = 0.43, P = 0.05, n = 21) and correlated with circulating HS fragments ( Figure 3 g, r = 0.59, P = 0.006, n = 19).